Two new biotech drugs for colorectal cancer, Avastin and Erbitux

Two new biotech drugs for colorectal cancer, Avastin and Erbitux, are making news.

Avastin (bevacizumab) is the first of a new kind...an angiogenesis inhibitor. It slows the growth of blood vessels that tumors need to grow.

It's approved for metastatic colorectal cancer...in combination with traditional chemotherapy. Avastin slows progression...and improves survival by about 5 months.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote